# PAX4

## Overview
PAX4 is a gene that encodes the paired box 4 protein, a transcription factor crucial for pancreatic development and the differentiation of beta cells, which are responsible for insulin production. The PAX4 protein is characterized by its paired domain, homeodomain, and transactivation domain, which facilitate its role in DNA binding and transcriptional regulation (Ko2023Pax4; Lorenzo2017The). As a transcriptional repressor, PAX4 influences the expression of key pancreatic hormones, ensuring the proper development and function of beta cells (Lorenzo2017The). Mutations in the PAX4 gene have been linked to various forms of diabetes, highlighting its clinical significance in glucose homeostasis and beta-cell survival (Lau2023PAX4; Ko2023Pax4).

## Structure
The PAX4 protein is a transcription factor involved in pancreatic development and beta-cell differentiation. It consists of approximately 350 amino acids and includes several key domains: a paired domain (PD), a homeodomain (HD), and a transactivation domain (TAD) (Ko2023Pax4; Lorenzo2017The). The paired domain is a bipartite structure with two helix-turn-helix motifs, which facilitate DNA binding and protein-protein interactions (Lorenzo2017The). The homeodomain also contributes to DNA binding, with consensus sequences identified for both domains (Smith1999PairedHomeodomain).

The C-terminal region of PAX4 contains a transactivation domain, whose activity is cell-type dependent, and a repressor domain that functions across various cell types (Fujitani1999Identification; Lorenzo2017The). The repressor domain is located between amino acids 278 and 349, while the transactivation domain spans amino acids 232 to 314 (Fujitani1999Identification).

PAX4 undergoes post-translational modifications, including SUMOylation, which affects its stability and interaction capabilities (Lorenzo2017The). The gene can produce alternatively spliced mRNA variants, resulting in protein isoforms with differences in their N- and C-terminal regions, impacting their transcriptional activity and interactions (Melnikova2020Alternative).

## Function
The PAX4 gene encodes a transcription factor that plays a critical role in the development and function of pancreatic β-cells, which are essential for insulin production and glucose homeostasis. In healthy human cells, PAX4 is involved in the proliferation and differentiation of β-cells, maintaining a functional β-cell mass crucial for proper glucose regulation (Lorenzo2017The). PAX4 acts as a transcriptional repressor, influencing the expression of key islet hormones by binding to their gene promoters. It represses glucagon, ghrelin, and insulin expression, ensuring the formation of single-hormone expressing cells and maintaining β-cells in an immature state (Lorenzo2017The).

PAX4 is active in the nucleus, where it regulates gene expression by binding to specific DNA sequences. It competes with PAX6 for binding sites, particularly on the glucagon gene promoter, to inhibit glucagon expression (Smith1999PairedHomeodomain). PAX4 also modulates the intrinsic apoptotic pathway, enhancing the expression of anti-apoptotic factors like Bcl-xL and Bcl-2, thereby protecting β-cells from apoptosis (Lorenzo2017The). This gene's expression is regulated by epigenetic modifications and is influenced by glucose levels, highlighting its adaptive role in β-cell function and survival (Lorenzo2017The).

## Clinical Significance
Mutations in the PAX4 gene are associated with several forms of diabetes, including type 1 diabetes (T1D), type 2 diabetes (T2D), and maturity-onset diabetes of the young (MODY). Specific mutations such as R121W, R133W, R164W, and R192H/S have been linked to these conditions. The R121W mutation impairs DNA binding and transcription activity, leading to T2D, particularly in Japanese populations (Ko2023Pax4; Shimajiri2001A). The R133W variant is associated with ketosis-prone diabetes (KPD) in individuals of West African descent, characterized by severe insulin deficiency (MauvaisJarvis2004PAX4). The R164W mutation is linked to MODY type 9 in Thai subjects, affecting Pax4's transcriptional repressor activity (Ko2023Pax4). The R192H/S variants are associated with early-onset T2D in Chinese populations, with decreased C-peptide levels and higher BMI (Gao2020Missense; Ko2023Pax4).

Alterations in PAX4 expression can also impact diabetes risk. Loss of PAX4 function is linked to decreased pancreatic beta cell function, increasing T2D risk (Lau2023PAX4). Overexpression of PAX4 can stimulate the conversion of alpha cells to beta-like cells, indicating its role in beta cell differentiation and survival (Panneerselvam2019PAX).

## Interactions
PAX4 is a transcription factor that interacts with various proteins and nucleic acids, playing a significant role in pancreatic development and beta-cell differentiation. It competes with PAX6 for binding sites on gene promoters, such as those for glucagon and insulin, leading to transcriptional repression. This competition is facilitated by the similarity in their DNA binding sequences, allowing PAX4 to inhibit the transcriptional activation of these genes by PAX6 (RitzLaser2002The; Ko2023Pax4).

PAX4 also interacts with the transcription factor Arx, which is essential for alpha cell development. PAX4 antagonizes Arx, promoting beta and delta cell fates while inhibiting alpha cell commitment (Ko2023Pax4). The interaction between PAX4 and PAX6 is crucial, as PAX4 can decrease the expression of target genes by blocking PAX6-dependent activation and through its own repressor domain (Lorenzo2017The).

PAX4's paired domain (PD) is involved in protein-protein interactions, similar to PAX6, and is necessary for its interaction with other transcription factors (Lorenzo2017The). PAX4 can also interact with proteins like NEUROD1 and NKX2-2, which are important for beta-cell differentiation and function (Sneha2018Probing). These interactions highlight PAX4's role in regulating gene expression critical for pancreatic development.


## References


[1. (RitzLaser2002The) B. Ritz-Laser, A. Estreicher, B. R. Gauthier, A. Mamin, H. Edlund, and J. Philippe. The pancreatic beta-cell-specific transcription factor pax-4 inhibits glucagon gene expression through pax-6. Diabetologia, 45(1):97–107, January 2002. URL: http://dx.doi.org/10.1007/s125-002-8249-9, doi:10.1007/s125-002-8249-9. This article has 59 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1007/s125-002-8249-9)

[2. (MauvaisJarvis2004PAX4) Franck Mauvais-Jarvis, Stuart B. Smith, Cédric Le May, Suzanne M. Leal, Jean-François Gautier, Mariam Molokhia, Jean-Pierre Riveline, Arun S. Rajan, Jean-Philippe Kevorkian, Sumei Zhang, Patrick Vexiau, Michael S. German, and Christian Vaisse. Pax4 gene variations predispose to ketosis-prone diabetes. Human Molecular Genetics, 13(24):3151–3159, October 2004. URL: http://dx.doi.org/10.1093/hmg/ddh341, doi:10.1093/hmg/ddh341. This article has 93 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1093/hmg/ddh341)

[3. (Gao2020Missense) Aibo Gao, Bin Gu, Juan Zhang, Chen Fang, Junlei Su, Haorong Li, Rulai Han, Lei Ye, Weiqing Wang, Guang Ning, Jiqiu Wang, and Weiqiong Gu. Missense variants in pax4 are associated with early-onset diabetes in chinese. Diabetes Therapy, 12(1):289–300, November 2020. URL: http://dx.doi.org/10.1007/s13300-020-00960-5, doi:10.1007/s13300-020-00960-5. This article has 5 citations and is from a peer-reviewed journal.](https://doi.org/10.1007/s13300-020-00960-5)

[4. (Melnikova2020Alternative) A. I. Melnikova, T. S. Krasnova, N. A. Zubkova, A. N. Tiulpakov, and P. M. Rubtsov. Alternative variants of pax4 human transcription factor: comparative transcriptional activity. Molecular Biology, 54(5):749–756, September 2020. URL: http://dx.doi.org/10.1134/S0026893320050076, doi:10.1134/s0026893320050076. This article has 0 citations and is from a peer-reviewed journal.](https://doi.org/10.1134/S0026893320050076)

[5. (Sneha2018Probing) P. Sneha, D. Thirumal Kumar, Jose Lijo, M. Megha, R. Siva, and C. George Priya Doss. Probing the Protein–Protein Interaction Network of Proteins Causing Maturity Onset Diabetes of the Young, pages 167–202. Elsevier, 2018. URL: http://dx.doi.org/10.1016/bs.apcsb.2017.07.004, doi:10.1016/bs.apcsb.2017.07.004. This article has 14 citations.](https://doi.org/10.1016/bs.apcsb.2017.07.004)

[6. (Smith1999PairedHomeodomain) Stuart B. Smith, Hooi C. Ee, Jennifer R. Conners, and Michael S. German. Paired-homeodomain transcription factor pax4 acts as a transcriptional repressor in early pancreatic development. Molecular and Cellular Biology, 19(12):8272–8280, December 1999. URL: http://dx.doi.org/10.1128/mcb.19.12.8272, doi:10.1128/mcb.19.12.8272. This article has 136 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1128/mcb.19.12.8272)

[7. (Lau2023PAX4) Hwee Hui Lau, Nicole A. J. Krentz, Fernando Abaitua, Marta Perez-Alcantara, Jun-Wei Chan, Jila Ajeian, Soumita Ghosh, Yunkyeong Lee, Jing Yang, Swaraj Thaman, Benoite Champon, Han Sun, Alokkumar Jha, Shawn Hoon, Nguan Soon Tan, Daphne Su-Lyn Gardner, Shih Ling Kao, E. Shyong Tai, Anna L. Gloyn, and Adrian Kee Keong Teo. Pax4 loss of function increases diabetes risk by altering human pancreatic endocrine cell development. Nature Communications, September 2023. URL: http://dx.doi.org/10.1038/s41467-023-41860-z, doi:10.1038/s41467-023-41860-z. This article has 8 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1038/s41467-023-41860-z)

[8. (Fujitani1999Identification) Yoshio Fujitani, Yoshitaka Kajimoto, Tetsuyuki Yasuda, Taka-Aki Matsuoka, Hideaki Kaneto, Yutaka Umayahara, Noriko Fujita, Hirotaka Watada, Jun-Ichi Miyazaki, Yoshimitsu Yamasaki, and Masatsugu Hori. Identification of a portable repression domain and an e1a-responsive activation domain in pax4: a possible role of pax4 as a transcriptional repressor in the pancreas. Molecular and Cellular Biology, 19(12):8281–8291, December 1999. URL: http://dx.doi.org/10.1128/mcb.19.12.8281, doi:10.1128/mcb.19.12.8281. This article has 49 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1128/mcb.19.12.8281)

[9. (Shimajiri2001A) Yoshinori Shimajiri, Tokio Sanke, Hiroto Furuta, Tadashi Hanabusa, Takayuki Nakagawa, Yoshio Fujitani, Yoshitaka Kajimoto, Nobuyuki Takasu, and Kishio Nanjo. A missense mutation of pax4 gene (r121w) is associated with type 2 diabetes in japanese. Diabetes, 50(12):2864–2869, December 2001. URL: http://dx.doi.org/10.2337/DIABETES.50.12.2864, doi:10.2337/diabetes.50.12.2864. This article has 150 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.2337/DIABETES.50.12.2864)

[10. (Panneerselvam2019PAX) Antojenifer Panneerselvam, Arun Kannan, Lezy Flora Mariajoseph-Antony, and Chidambaram Prahalathan. Pax proteins and their role in pancreas. Diabetes Research and Clinical Practice, 155:107792, September 2019. URL: http://dx.doi.org/10.1016/j.diabres.2019.107792, doi:10.1016/j.diabres.2019.107792. This article has 27 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.diabres.2019.107792)

[11. (Ko2023Pax4) Jenna Ko, Vivian A. Fonseca, and Hongju Wu. Pax4 in health and diabetes. International Journal of Molecular Sciences, 24(9):8283, May 2023. URL: http://dx.doi.org/10.3390/ijms24098283, doi:10.3390/ijms24098283. This article has 5 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/ijms24098283)

[12. (Lorenzo2017The) Petra Lorenzo, Francisco Juárez-Vicente, Nadia Cobo-Vuilleumier, Mario García-Domínguez, and Benoit Gauthier. The diabetes-linked transcription factor pax4: from gene to functional consequences. Genes, 8(3):101, March 2017. URL: http://dx.doi.org/10.3390/genes8030101, doi:10.3390/genes8030101. This article has 35 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/genes8030101)